Monday, September 10, 2012
The prestigious scientific journal British Journal of Oral & Maxillofacial Surgery has published a study on treating Bisphosphonate-associated osteonecrosis of the jaw (BRONJ) with PRGF®-Endoret® technology (Plasma Rich in Growth Factors)
The prestigious scientific journal British Journal of Oral & Maxillofacial Surgery has published a study on treating Bisphosphonate-associated osteonecrosis of the jaw (BRONJ) with PRGF®-Endoret® technology (Plasma Rich in Growth Factors)
BRONJ is characterised by necrosis in the jaw bone of patients recieving biphosphonates that lasts for more than 8 weeks. The paper, by Dr. Eduardo Anitua, founder and scientific director of BTI Biotechnology Institute, Dr. Leire Begoña and Dr. Gorka Orive, demonstrates that the combination of surgery and PRGF®-Endoret® can be considered a new and effictive way to treat the disease
As the current treatments available are limited, Dr. Anitua has developed a new treatment protocol that combines the surgical resection of the nectrotic bone and the application of PRGF®-Endoret®.
The results of their research demonstrate the efficacy of PRGF®-Endoret® in the treatment of unilateral mandibular paresthesia in a patient with BRONJ, for whom conservative therapy had not been successful. The success of the treatment was evident in the resolution of the pain, the closure of the gingival ulcer and the regeneration of the bone defect. In addition, the nerve function was restored and, consequently, the patient's quality of life was improved.
